Miromatrix Medical Inc. (NASDAQ:MIRO) Short Interest Update

Miromatrix Medical Inc. (NASDAQ:MIRO) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 230,200 shares, an increase of 2,156.9% from the December 15th total of 10,200 shares. Approximately 1.7% of the shares of the company are sold short. Based on an average daily trading volume, of 29,500 shares, the short-interest ratio is currently 7.8 days.

Shares of NASDAQ MIRO opened at $3.94 on Friday. Miromatrix Medical has a one year low of $3.71 and a one year high of $16.52. The stock’s fifty day moving average is $5.96. The company has a debt-to-equity ratio of 0.01, a quick ratio of 17.58 and a current ratio of 17.58.

Miromatrix Medical (NASDAQ:MIRO) last issued its earnings results on Monday, November 15th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The business had revenue of $0.01 million for the quarter.

Several large investors have recently added to or reduced their stakes in the company. First Light Asset Management LLC acquired a new position in shares of Miromatrix Medical during the 2nd quarter valued at about $5,534,000. RTW Investments LP acquired a new position in shares of Miromatrix Medical during the 2nd quarter valued at about $3,262,000. AWM Investment Company Inc. acquired a new position in shares of Miromatrix Medical during the 2nd quarter valued at about $1,340,000. Manatuck Hill Partners LLC acquired a new position in shares of Miromatrix Medical during the 2nd quarter valued at about $1,165,000. Finally, Millennium Management LLC acquired a new position in shares of Miromatrix Medical during the 2nd quarter valued at about $654,000. 15.58% of the stock is owned by institutional investors and hedge funds.

About Miromatrix Medical

Miromatrix Medical Inc engages in the development of biological human organs to solve the chronic shortage of transplantable organs. The company also develops organ-derived biological products for various applications, such as soft tissue reinforcement and wound care. It uses its perfusion decellularization/recellularization technology to engineer transplantable organs for the people who need them.

Featured Article: What is a Derivative?

Receive News & Ratings for Miromatrix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miromatrix Medical and related companies with MarketBeat.com's FREE daily email newsletter.